Johnson & Johnson’s $2 Billion Investment in North Carolina

On Thursday, Johnson & Johnson revealed plans for a significant $2 billion investment to establish a manufacturing facility in North Carolina. This initiative aims to enhance domestic production, particularly as President Trump considers imposing steep tariffs on pharmaceutical imports.

Alongside J&J, companies like Eli Lilly and AstraZeneca are also committing substantial funds to bolster U.S. manufacturing amidst Trump’s proposed import duties.

Earlier this month, Trump detailed a phased approach to drug tariffs, starting modestly but potentially escalating to as high as 250%.

To support this new facility, J&J has entered into a decade-long agreement with Fujifilm Diosynth, a Tokyo-based contract development firm. The new plant will cover more than 160,000 square feet.

This collaboration is expected to create about 120 jobs, further expanding the company’s manufacturing footprint in the United States.

Trump’s threat of a 250% tariff was reinforced during an August television appearance, where he first mentioned a 200% tariff during a meeting with Irish officials in March.

He proposed a gradual implementation, starting with lower tariffs that could escalate to 150% and then reach the 250% ceiling over the next 18 months.

Earlier this year, the Trump administration initiated a Section 232 investigation into drug imports, a legal framework previously used to impose tariffs on steel and aluminum, to assess whether reliance on foreign drug production compromises U.S. national security.

However, the looming tariffs were somewhat mitigated this week when the U.S. reached an agreement to limit drug tariffs on imports from the European Union to just 15%.

This agreement, set to take effect on September 1, will impose minimal tariffs on generic medications from Europe while placing a 15% fee on branded drugs.